Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Targeting TIGIT: Understanding New Approaches for Inhibiting the Immune Checkpoint Pathway

Source: Novel Immunotherapy Approaches Targeting TIGIT: Updates and Perspectives for the Oncology Care Team
Listen to Drs. Jyoti Patel and Diwakar Davar as they discuss the latest research on TIGIT, the exciting emerging target in immune checkpoint inhibitors.
person default
Diwakar Davar, MD
person default
Jyoti D. Patel, MD
Released: April 7, 2022

In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01.

Information on this Educational Activity

Faculty

Diwakar Davar, MD

Assistant Professor
Melanoma and Phase I Therapeutics
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania

Jyoti D. Patel, MD, has disclosed that she has received funds for research from AstraZeneca, and has been and advisor for Abbvie and Takeda.
Jyoti D. Patel, MD

Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Diwakar Davar, MD, has disclosed that he has received funds for research support from Arcus, CellSight Technologies, Checkmate Pharmaceuticals, GlaxoSmithKline/Tesaro, Immunocore, and Merck and consulting fees from Checkmate Pharmaceuticals, Finch, Shionogi, and Vedanta.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

AMBER trial of cobolimab and dostarlimab shows manageable safety in advanced solid tumors and promising activity in advanced melanoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 20, 2022

CheckMate 067 7.5-year follow-up with nivolumab + ipilimumab in advanced melanoma, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Update of ATEZO-BRAIN trial evaluating atezolizumab plus chemotherapy in patients with advanced nonsquamous NSCLC with untreated brain metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 16, 2022

Data from the TRICOTEL study of the combination of atezolizumab, cobimetinib, and vemurafenib in advanced BRAFV600-mutated melanoma with CNS metastases, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Released: June 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings